mTOR, translation initiation and cancer
The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Abstract
Control of mRNA translation plays a fundamental role in many aspects of cell metabolism. It constitutes a critical step in the control of gene expression, and consequently cell growth, proliferation and differentiation. Translation is regulated in response to nutrient availability, hormones, mitogenic and growth factor stimulation and is coupled with cell cycle progression and cell growth. Signaling by the PI3K/Akt/mTOR pathway profoundly affects mRNA translation through phosphorylation of downstream targets such as 4E-BP and S6K. Inhibitors of this pathway and thus cap-dependent translation are emerging as promising therapeutic options for the treatment of cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Such a shift has been associated with proliferation in tumorigenesis, and has been linked to the translational control of RPs (Mamane et al., 2006; Ruggero and Sonenberg, 2005).”
From Ribosome Profiling of Mouse Embryonic Stem Cells Reveals the Complexity and Dynamics of Mammalian Proteomes (2011) · cites this paper as Mamane et al., 2006
Citations
Cites
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181 · cited 5×
“…factors and hormones) with aminoacid availability and intracellular energy status to control translation rates and additional metabolic processes (Hay and Sonenberg, 2004) (Figure 2). mTOR has received considerable attention, as rapamycin (Rapamune) is a specific inhibitor of mTOR activity (for…”
BackgroundInfluentialSelf-citationExploiting the PI3K/AKT Pathway for Cancer Drug Discovery
Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1902 · Cited by 2,185 · cited 1×
“An important downstream target of this signaling pathway is cap-dependent mRNA translation (Hay and Sonenberg, 2004; Hennessy et al., 2005; Stephens et al., 2005; Petroulakis et al., 2006) (Figure 2). mTOR promotes the phosphorylation and activation of S6K and the hierarchial phosphorylation the…”
BackgroundeIF4 Initiation Factors: Effectors of mRNA Recruitment to Ribosomes and Regulators of Translation
Gingras, A.-C., Raught, B., & Sonenberg, N. (1999) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.68.1.913 · Cited by 2,121 · cited 4×
“The cap structure, m7GpppN (where N is any nucleotide), is present at the 50 terminus of all cellular eucaryotic mRNAs (except those in organelles) (Gingras et al., 1999b).”
BackgroundInfluentialSelf-citationRegulation of 4E-BP1 phosphorylation: a novel two-step mechanism
Gingras, A.-C., Gygi, S. P., Raught, B., Polakiewicz, R. D., Abraham, R. T., Hoekstra, M. F., Aebersold, R., & Sonenberg, N. (1999) · Genes & Development · doi:10.1101/gad.13.11.1422 · Cited by 1,343 · cited 4×
“The cap structure, m7GpppN (where N is any nucleotide), is present at the 50 terminus of all cellular eucaryotic mRNAs (except those in organelles) (Gingras et al., 1999b).”
BackgroundInfluentialSelf-citationHolz, M. K., Ballif, B. A., Gygi, S. P., & Blenis, J. (2005) · Cell · doi:10.1016/j.cell.2005.10.024 · Cited by 1,262
Pause, A., Belsham, G. J., Gingras, A.-C., Donzé, O., Lin, T.-A., Lawrence, J. C., & Sonenberg, N. (1994) · Nature · doi:10.1038/371762a0 · Cited by 1,239 · cited 1×
“…Heat and Acid-Stable protein regulated by Insulin) and 4E-BP2, were identified in a screen using radiolabelled recombinant eIF4E protein to probe a human placenta expression library (Pause et al., 1994) and by sequencing the complementary DNA (cDNA) clone for PHAS-I (Hu et al., 1994).”
BackgroundSelf-citationMammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E
Fingar, D. C., Salama, S., Tsou, C., Harlow, E., & Blenis, J. (2002) · Genes & Development · doi:10.1101/gad.995802 · Cited by 1,093 · cited 1×
“Enhancement of the eIF4E/4E-BP interaction, through the expression of a constitutively active 4E-BP mutant (all phosphorylation sites mutated to Ala), leads to a decrease in cell size and inhibition of cell cycle progression in a manner that mimics rapamycin treatment (Fingar et al., 2002, 2004).”
BackgroundKim, D.-H., Sarbassov, D. D., Ali, S. M., Latek, R. R., Guntur, K. V. P., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00114-x · Cited by 961 · cited 1×
“…et al., 2005; Stephens et al., 2005; Petroulakis et al., 2006) (Figure 2). mTOR promotes the phosphorylation and activation of S6K and the hierarchial phosphorylation the 4E-BPs (Gingras et al., 2001; Jacinto and Hall, 2003; Kim et al., 2003; Ruggero and Pandolfi, 2003; Kim and Sabatini, 2004).”
BackgroundMalignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap
Lazaris-Karatzas, A., Montine, K. S., & Sonenberg, N. (1990) · Nature · doi:10.1038/345544a0 · Cited by 956 · cited 1×
“…binding (Gingras et al., 1999b). eIF4G recruits the 40S small ribosomal subunit to the mRNA through the ribosomeassociated eIF3. eIF4E eIF4E was the first translation factor shown to cause malignant transformation when overexpressed in cul- tured rodent cells (Lazaris-Karatzas et al., 1990).”
BackgroundSelf-citationSurvival signalling by Akt and eIF4E in oncogenesis and cancer therapy
Wendel, H.-G., Stanchina, E. D., Fridman, J. S., Malina, A., Ray, S., Kogan, S., Cordon-Cardo, C., Pelletier, J., & Lowe, S. W. (2004) · Nature · doi:10.1038/nature02369 · Cited by 951 · cited 1×
“Furthermore, two groups independently demonstrated that eIF4E promotes lymphomagenesis in cooperation with Myc in transgenic mice (Ruggero et al., 2004; Wendel et al., 2004).”
Background
Cited by
Items 201–300 of 618
Agrawal, P., Chen, Y., Schilling, B., Gibson, B. W., & Hughes, R. E. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.328021 · Cited by 66
“ThemTOR substrate eIF4E-binding protein is critical for mTOR mediated regulation of cap-dependent translation (8).”
BackgroundLee, Y., Wu, W., Ji, W., Chen, J. Y., Cheng, Y., Chiang, M., & Chen, H. (2012) · Journal of Biomedical Science · doi:10.1186/1423-0127-19-9 · Cited by 64
“Besides, mTORC1, the downstream factor of Akt, is also critical for cell proliferation and correlated to carcinogenesis [51].”
BackgroundRapamycin Is a Potent Inhibitor of Skin Tumor Promotion by 12- O -Tetradecanoylphorbol-13-Acetate
Checkley, L. A., Rho, O., Moore, T., Hursting, S., & DiGiovanni, J. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0375 · Cited by 60
“mTOR is a serine/threonine protein kinase that regulates cellular growthandproliferationbycontrolling protein synthesis (6).”
BackgroundBMP-2 induces angiogenesis by provoking integrin α6 expression in human endothelial progenitor cells
Chen, W.-C., Chung, C., Lu, Y., Wu, M., Chou, P.-H., Yen, J.-Y., Lai, Y., Wang, G., Liu, S., Cheng, J., et al. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.02.021 · Cited by 67
Zhao, S., Dejanovic, D., Yao, P., Bhilocha, S., Sadler, T., Schirbel, A., West, G., Doyon, G., Lopez, R., Mao, R., et al. (2020) · Mucosal Immunology · doi:10.1038/s41385-020-0259-9 · Cited by 59
Zhang, M., Fu, W., Prabhu, S., Moore, J. C., Ko, J., Kim, J. W., Druker, B. J., Trapp, V., Fruehauf, J. P., Gram, H., et al. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00477-08 · Cited by 64
“Specifically, we were interested in small molecules that might interfere with translation initiation and with the efficient assembly of polysomal mRNA, since both processes have been implicated in several cancer types (15), in addition to CML (22).”
BackgroundResultAuner, H. W., Moody, A. M., Ward, T. H., Kraus, M., Milan, E., May, P. C., Chaidos, A., Driessen, C., Cenci, S., Dazzi, F., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074415 · Cited by 59
“Phosphorylation of ribosomal protein S6 (S6P) correlates with an increase in translation of mRNA transcripts that contain an oligopyrimidine tract in their 5' untranslated regions [51].”
BackgroundHuman Cytomegalovirus Induces Multiple Means To Combat Reactive Oxygen Species
Tilton, C., Clippinger, A. J., Maguire, T. G., & Alwine, J. C. (2011) · Journal of Virology · doi:10.1128/jvi.05572-11 · Cited by 66
“A primary function of mTORC1 is to control cap-dependent translation (37, 46, 49).”
BackgroundIgarashi, P., & Somlo, S. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007030299 · Cited by 56
Autophagy in 5-Fluorouracil Therapy in Gastrointestinal Cancer: Trends and Challenges
Tang, J.-C., Feng, Y.-L., Liang, X., & Cai, X.-J. (2016) · Chinese Medical Journal · doi:10.4103/0366-6999.176069 · Cited by 54
“[62] Activation of PI3K results in sequential AKT and mTOR activation, ultimately suppressing autophagy.[63,64] Inhibition of autophagy results in enhanced apoptosis following treatment with PI3K inhibitors, in particular, dual‐targeted PI3K/mTOR inhibitors.”
BackgroundJiang, X., Wang, Y., Qin, Y., He, W., Benlahrech, A., Zhang, Q., Jiang, X., Lu, Z., Ji, G., & Zheng, Y. (2017) · Scientific Reports · doi:10.1038/srep41964 · Cited by 59
Metformin efficacy and safety for colorectal polyps: a double-blind randomized controlled trial
Higurashi, T., Takahashi, H., Endo, H., Hosono, K., Yamada, E., Ohkubo, H., Sakai, E., Uchiyama, T., Hata, Y., Fujisawa, N., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-118 · Cited by 55
“The best-characterized downstream effector of mTOR is S6 kinase, which regulates the initiation and elongation phases of translation [28].”
BackgroundSathe, A., Chalaud, G., Oppolzer, I. A., Wong, K. Y., von Busch, M., Schmid, S. C., Tong, Z., Retz, M. M., Gschwend, J. E., Schulz, W. A., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0190854 · Cited by 61
“Phosphorylated S6K1 promotes the translation of 5’-terminal oligopyrimidine mRNAs while phosphorylation of 4E-BP1 prevents its binding to eIF4E and increases cap-dependent translation, thus controlling cellular protein synthesis and cell growth [5].”
BackgroundBiological Effects of the Pim Kinase Inhibitor, SGI-1776, in Multiple Myeloma
Cervantes-Gomez, F., Chen, L. S., Orlowski, R. Z., & Gandhi, V. V. (2013) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2013.05.019 · Cited by 58
“Similar to Pim kinase-mediated protein translation, mammalian target of rapamycin (mTOR) also signals for cap-dependent protein translation.(42) mTOR regulates protein synthesis by hyperphosphorylating 4E-BP1 and decreasing its affinity for the translation initiation factor eIF4E.”
BackgroundLow, W., Dang, Y., Bhat, S., Romo, D., & Liu, J. O. (2007) · Chemistry & Biology · doi:10.1016/j.chembiol.2007.05.012 · Cited by 54
Disruption of Prostate Epithelial Differentiation Pathways and Prostate Cancer Development
Frank, S. B., & Miranti, C. K. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00273 · Cited by 67
“Activated Akt phosphorylates and activates the mTORC1 complex, which in turn regulates a range of targets such as S6K and 4EBP1, both of which are required for protein synthesis (240).”
BackgroundThe ATPase hCINAP regulates 18S rRNA processing and is essential for embryogenesis and tumour growth
Bai, D., Zhang, J., Li, T., Hang, R., Liu, Y., Tian, Y., Huang, D., Qu, L., Cao, X., Ji, J., et al. (2016) · Nature Communications · doi:10.1038/ncomms12310 · Cited by 57
“…correlated with translational regulation, increased cancer susceptibility associated with altered ribosomal activity may be due to an increased protein synthesis rate and selection of specific cancer-associated messenger RNAs for translation 10,17,18 , as in the case of congenital dyskeratosis 19 .”
A class IA PI3K controls inflammatory cytokine production in human neutrophils
Fortin, C. F., Cloutier, A., Ear, T., Sylvain‐Prévost, S., Mayer, T. Z., Bouchelaghem, R., & McDonald, P. P. (2011) · European Journal of Immunology · doi:10.1002/eji.201040945 · Cited by 55
Zhai, Y., Zhong, Z., Chen, C. A., Xia, Z., Ling, S., Blackburn, M. R., & Shyu, A. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01237-08 · Cited by 56
“However, eIF4E is released from hyperphosphorylated 4E-BP1 as a result of consecutive phosphorylation of 4E-BP1, with Ser 65 being phosphorylated last via the phosphatidylinositol-3 kinase/Akt/ mTOR pathway (24, 44).”
BackgroundFluorescence-Based Detection and Quantification of Features of Cellular Senescence
Cho, S., & Hwang, E. S. (2011) · Methods in cell biology · doi:10.1016/b978-0-12-385493-3.00007-3 · Cited by 61
Jewer, M., Findlay, S. D., & Postovit, L.-M. M. (2012) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-012-0179-x · Cited by 63
“Regulation of translation is important for maintaining the balance between apoptotic and cell survival signals (Mamane et al. 2006).”
InfluentialActivation of cap-independent translation by variant eukaryotic initiation factor 4G in vivo
Kaiser, C., Dobrikova, E. Y., Bradrick, S. S., Shveygert, M., Herbert, J. T., & Gromeier, M. (2008) · RNA · doi:10.1261/rna.1171808 · Cited by 59
“Translation control provides a critical level of gene regulation, which has been implicated in the malignant phenotype (Bader and Vogt 2004; Mamane et al. 2004, 2006).”
BackgroundDobashi, Y., Suzuki, S., Matsubara, H., Kimura, M., Endo, S., & Ooi, A. (2008) · Cancer · doi:10.1002/cncr.23996 · Cited by 53
“Akt transduces signals to various molecules, including the tuberous sclerosis complex (TSC) protein.(8,9) Akt inhibits the activity of TSC, which leads to activation of the molecule farther downstream, mammalian target of rapamycin (mTOR), which is a 289-kD serine/threonine (Ser/Thr) protein kinase.”
BackgroundInfluentialGeorge, A., Panda, S., Kudmulwar, D., Chhatbar, S. P., Nayak, S. C., & Krishnan, H. H. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.308916 · Cited by 54
“PI3K regulatesmTOR either via AKT or independent of it, which in turn regulates translation initiation through 4EBP1 (54, 55).”
BackgroundOrigin and plasticity of MHC I-associated self peptides
de Verteuil, D. A., Granados, D. P., Thibault, P., & Perreault, C. (2011) · Autoimmunity Reviews · doi:10.1016/j.autrev.2011.11.003 · Cited by 55
mTOR Regulation of Lymphoid Cells in Immunity to Pathogens
Keating, R., & McGargill, M. A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00180 · Cited by 51
Aberrant Receptor Signaling and Trafficking as Mechanisms in Oncogenesis
Rusten, T. E., Haglund, K., & Stenmark, H. (2007) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.v13.i1.20 · Cited by 60
Karar, J., Cerniglia, G. J., Lindsten, T., Koumenis, C., & Maity, A. M. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.21144 · Cited by 49
“Many of these are associated with cell proliferation or survival including cyclin D1, cyclin B1, survivin and vascular endothelial growth factor (VEGF).(11,20,21) We compared the effects of BEZ235 to a known inhibitor of the eIF4E-eIF4G interaction, 4EGI1.”
BackgroundZhao, Y., Zheng, D., & Cvekl, A. (2018) · Experimental Eye Research · doi:10.1016/j.exer.2018.06.004 · Cited by 64
“As previously reported in cancer cells (Mamane et al., 2006), Mtor could induce phosphorylation of p70S6K, Eif4ebp1 and cause their dissociation from Eif3 and Eif4e respectively, inducing the translation initiation (Fig.”
Vadysirisack, D. D., & Ellisen, L. W. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-430-8_4 · Cited by 47
“Regulation of cap-dependent translation initiation by mTORC1 involves the direct phosphorylation of its downstream substrates eukaryotic initiation factor 4E binding protein 1 (4E-BP1) and ribosomal protein kinase S6 (p70S6K) (8-10).”
BackgroundClippinger, A. J., & Alwine, J. C. (2012) · Genes & Development · doi:10.1101/gad.196147.112 · Cited by 53
“…mTORC1 in translational control has been well-established; mTORC1mediated phosphorylation of p70 S6 kinase (S6K) and the eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) is necessary for the maintenance of translation (Sarbassov et al. 2005; Mamane et al. 2006; Reiling and Sabatini 2006).”
Liu, G., Shi, F., Jia, L., Wang, C., Fu, Y., & Luo, Y. (2018) · Oncogene · doi:10.1038/s41388-017-0062-6 · Cited by 50
Proteome-Wide Profiling of the MCF10AT Breast Cancer Progression Model
Choong, L., Lim, S., Chong, P. K., Wong, C. Y., Shah, N. H., & Lim, Y. P. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011030 · Cited by 48
“This is perhaps not surprising since metabolism is an Achilles’ heel in cancer biology [41]; For instance, aberrant PI3K/AKT pathway during cancer development inadvertently amplifies glucose metabolism and translational activities via glucose transporter (GLUT4), mTOR/S6K/eukaryotic initiation factor 4E-binding protei…”
BackgroundHu, J., Straub, J., Xiao, D., Singh, S. V., Yang, H., Sonenberg, N., & Vatsyayan, J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0392 · Cited by 49
“However, evidence is accumulating to indicate that targeting protein translation represents one of the most promising approaches for cancer intervention (3).”
BackgroundSelf-citationHan, X., & Sun, Z. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.14642 · Cited by 51
“The mTOR functions as a component of 2 large complexes; mTORC1 in coordination with mTORC2 plays critical role in regulating cell growth and homeostasis.(38,39) Several lines of evidence show that the mTOR signaling regulates aging, and inhibition of this pathway extends life span in various models.”
BackgroundReassessment of the role of FKBP38 in the Rheb/mTORC1 pathway
Uhlenbrock, K., Weiwad, M., Wetzker, R., Fischer, G. S., Wittinghofer, A., & Rubio, I. (2009) · FEBS Letters · doi:10.1016/j.febslet.2009.02.015 · Cited by 47
“The Ser/Thr kinase mTOR affects protein translation by regulating the activity of the ribosomal S6 protein kinase (p70 S6 kinase) and the translation initiation factor binding protein 4E-BP1 [1,2].”
BackgroundNo, J. H., Jeon, Y. T., Park, I.-A., Kim, Y.-B., Kim, J., Park, N.-H., Kang, S., Han, H. J., Lim, J. M., & Song, Y. S. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.12.364 · Cited by 53
“Recent studies suggest that the mTOR pathway has a crucial role in the regulation of translation of specific proteins associated with cancer progression [3,4].”
BackgroundCastellví, J., García, Á., Ruiz-Marcellán, C., Hernández‐Losa, J., Peg, V., Salcedo, M., Gil‐Moreno, A., & y Cajal, S. R. (2009) · Human Pathology · doi:10.1016/j.humpath.2008.12.019 · Cited by 46
“We have previously demonstrated the importance of cell growth signaling pathways in breast, ovarian, colon, and prostate carcinomas [18-20], and they have been described also in many other tumors [21].”
BackgroundSaha, P., & Datta, K. (2018) · Oncotarget · doi:10.18632/oncotarget.24082 · Cited by 49
“com/oncotarget like PTEN which usually inhibit the pathway [114, 115].”
BackgroundYeager, N., Brewer, C., Cai, K. Q., Xu, X., & Cristofano, A. D. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3030 · Cited by 49
“In fact, mTOR downstream targets, S6K1 and ribosomal protein S6 (21), were found to be phosphorylated upon Pten loss, and their activation status returned to undetectable levels upon RAD001 treatment (Fig.”
Gordon, I. K., Ye, F., & Kent, M. S. (2008) · American Journal of Veterinary Research · doi:10.2460/ajvr.69.8.1079 · Cited by 56
Yang, T. T. C., Yu, R. Y.-L., Agadir, A., Gao, G., Campos‐González, R., Tournier, C., & Chow, C.-W. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01847-07 · Cited by 52
“Target of rapamycin (TOR) signaling contributes to cell growth and differentiation in organisms ranging from yeast to mammals (18, 23, 31, 37).”
BackgroundSharp, Z. D., & Strong, R. (2010) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glp212 · Cited by 46
Wilson, F. A., Suryawan, A., Orellana, R. A., Kimball, S. R., Gazzaneo, M. C., Nguyen, H. V., Fiorotto, M. L., & Davis, T. A. (2009) · Journal of Nutrition · doi:10.3945/jn.109.106781 · Cited by 50
Selective inhibition of β-F1-ATPase mRNA translation in human tumours
Willers, I. M., Isidoro, A., Ortega, A. D., Fernández, P. L., & Cuezva, J. M. (2010) · Biochemical Journal · doi:10.1042/bj20091570 · Cited by 56
Parameters of protection against ultraviolet radiation‐induced skin cell damage
Cao, C., & Wan, Y. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21780 · Cited by 47
“S6K1 is another mTOR target that plays a role in the apoptosis resistance of cancer cells (Wang et al., 2003; Panner et al., 2005; Mamane et al., 2006).”
BackgroundTRIBE editing reveals specific mRNA targets of eIF4E-BP in Drosophila and in mammals
Jin, H., Na, D., Rahman, R., Xu, W., Fieldsend, A., Song, W., Liu, S., Li, C. V., & Rosbash, M. (2020) · Science Advances · doi:10.1126/sciadv.abb8771 · Cited by 44
“, it impacts cancer, proper neuronal activity and mammalian circadian entrainment (Teleman et al. 2005; Tettweiler et al. 2005; Mamane et al. 2006; Zid et al. 2009; Cao et al. 2013).”
BackgroundLiu, D., Huang, Y., Chen, B., Zeng, J., Guo, N., Zhang, S., Liu, L., Xu, H., Mo, X., & Li, W. (2011) · Cancer · doi:10.1002/cncr.25959 · Cited by 46
“regulation of cell growth through activating P70 ribosomal protein S6 kinase (P70S6K).(9) Up-regulation of P70S6K also contributes to tumorigenesis.”
BackgroundCarvalho, G. B., Drago, I., Hoxha, S., Yamada, R., Mahneva, O., Bruce, K. D., Soto Obando, A., Conti, B., & Ja, W. W. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1618994114 · Cited by 44
“The protein kinase mTOR is involved in cell growth and differentiation and acts as one of the main regulators of 4E-BP function (35).”
BackgroundWolf, A., Rietscher, K., Glaß, M., Hüttelmaier, S., Schutkowski, M., Ihling, C. H., Sinz, A., Wingenfeld, A., Mun, A., & Hatzfeld, M. (2013) · Journal of Cell Science · doi:10.1242/jcs.118992 · Cited by 51
“Growth factor signaling cascades modulate the activity of translation initiation factors by controlling their phosphorylation (Raught et al., 2004; Svitkin et al., 2005; Mamane et al., 2006; She et al., 2010).”
BackgroundRoles of GSK3 in metabolic shift toward abnormal anabolism in cell senescence
Kim, Y., Seo, Y., Park, C., Yoon, S., & Yoon, G. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05617.x · Cited by 41
Jacinto, E. (2008) · IUBMB Life · doi:10.1002/iub.56 · Cited by 43
“In mammals, amino acid starvation or rapamycin treatment both lead to dephosphorylation of the mTORC1 translation targets S6K and 4E-BP (62, 63).”
BackgroundLi, A., Fan, S., Xu, Y., Meng, J., Shen, X., Mao, J., Zhang, L., Zhang, X., Moeckel, G., Wu, D., et al. (2017) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13091 · Cited by 42
Zhang, Y.-J., Tian, X.-Q., Sun, D.-F., Zhao, S.-L., Xiong, H., & Fang, J.-Y. (2009) · Cancer Investigation · doi:10.1080/07357900802314893 · Cited by 42
“For these reasons, mTOR is currently under investigation as a potential target for anticancer therapy (4, 5).”
BackgroundInhibition of mTORC1 inhibits lytic replication of Epstein-Barr virus in a cell-type specific manner
Adamson, A. L., Le, B. T., & Siedenburg, B. D. (2014) · Virology Journal · doi:10.1186/1743-422x-11-110 · Cited by 42
“Rapamycin, also an immunosuppressant, complexes with the protein FKBP-12; this complex then binds to mTOR and inhibits its kinase activity [16].”
BackgroundStimulation of ovarian follicle growth after AMPK inhibition
Lu, X., Guo, S., Cheng, Y., Kim, J.-H., Feng, Y., & Feng, Y. (2017) · Reproduction · doi:10.1530/rep-16-0577 · Cited by 46
mTOR at the Transmitting and Receiving Ends in Tumor Immunity
Guri, Y., Nordmann, T. M., & Roszik, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00578 · Cited by 43
Expression and activity of eIF6 trigger Malignant Pleural Mesothelioma growthin vivo
Miluzio, A., Oliveto, S., Pesce, E., Mutti, L., Murer, B., Grosso, S., Ricciardi, S., Brina, D., & Biffo, S. (2015) · Oncotarget · doi:10.18632/oncotarget.5462 · Cited by 42
“The best-characterized oncogenic signalling acting on initiation is driven by the PI3K-AKT-mTOR pathway that ultimately regulates eIF4F activation and 48S formation [7].”
PDGF/VEGF signaling controls cell size in Drosophila
Sims, D., Duchek, P., & Baum, B. (2009) · Genome biology · doi:10.1186/gb-2009-10-2-r20 · Cited by 47
Ding, J., Romani, J., Zaborski, M., MacLeod, R. A. F., Nagel, S., Drexler, H. G., & Quentmeier, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083510 · Cited by 44
“S6 generally controls the cap-dependent translation of mRNAs [39,48].”
BackgroundLi, S.-H., Chen, C.-H., Lu, H.-I., Huang, W., Tien, W.-Y., Lan, Y.-C., Lee, C.-C., Chen, Y.-H., Huang, H.-Y., Chang, A. Y., et al. (2014) · Surgery · doi:10.1016/j.surg.2014.10.014 · Cited by 41
Salles, M., Hervé, D., Rivet, J., Longueville, S., Millan, M. J., Girault, J., & la Cour, C. M. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12206 · Cited by 47
“Activated mTORC1 phosphorylates two substrates, p70S6 kinase (p70S6K), leading in turn to phosphorylation of the ribosomal protein S6 (rpS6) on Ser235/236 and Ser240/244, and eIF4E binding protein 1 (4E–BP1), an inhibitor of the initiation factor eIF4E (Mamane et al. 2006; Foster and Fingar 2010).”
BackgroundJohnson, M. D., O’Connell, M., Vito, F., & Bakos, R. S. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9746-7 · Cited by 46
Razmara, M., Heldin, C., & Lennartsson, J. (2013) · Cell Communication and Signaling · doi:10.1186/1478-811x-11-3 · Cited by 51
“Akt-mediated phosphorylation which inactivates the TSC1/2 complex [8-10].”
BackgroundRoles of host and viral microRNAs in human cytomegalovirus biology
Dhuruvasan, K., Sivasubramanian, G., & Pellett, P. E. (2010) · Virus Research · doi:10.1016/j.virusres.2010.10.011 · Cited by 46
Villena, J., Aso, H., & Kitazawa, H. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00421 · Cited by 44
“It was also reported that TGF-β induces ERK activity in IECs and this TGF-β/ERK interaction regulates genes that are crucial for cell growth, migration, and survival of IECs (71, 72).”
BackgroundYu, Y., Tian, L., Xiao, F., Cheng, J. Q., Gong, Y., Liu, X., Zhang, Z., Yang, X., He, S., Li, C., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.02.052 · Cited by 41
Liu, X., Zeng, S., Liu, S., Wang, G., Lai, H., Zhao, X., Bi, S., Guo, D., Chen, X., Yi, H., et al. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.553563 · Cited by 46
mTORC2 Balances AKT Activation and eIF2α Serine 51 Phosphorylation to Promote Survival under Stress
Tenkerian, C., Krishnamoorthy, J., Mounir, Z., Kazimierczak, U., Khoutorsky, A., Staschke, K. A., Kristof, A. S., Wang, S., Hatzoglou, M., & Koromilas, A. E. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0184-t · Cited by 42
“mTOR is intimately involved in mRNA translation inasmuch as mTORC1 activation leads to stimulation of cap-dependent mRNA translation whereas mTORC2 activation depends on binding to actively translating polyribosomes (23, 24).”
BackgroundTargeting mTOR for the treatment of B cell malignancies
Lee, J. S., Vo, T.-T. T., & Fruman, D. A. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12888 · Cited by 45
mTOR- and LARP1-dependent regulation of TOP mRNA poly(A) tail and ribosome loading
Ogami, K., Oishi, Y., Sakamoto, K., Okumura, M., Yamagishi, R., Inoue, T., Hibino, M., Nogimori, T., Yamaguchi, N., Furutachi, K., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111548 · Cited by 45
Sokolova, O. V., Vieth, M. W., Gnad, T., Bozko, P. M., & Naumann, M. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2014.08.023 · Cited by 40
MNK, EIF4E and targeting translation for therapy
Silva, R. L. A., & Wendel, H. (2008) · Cell Cycle · doi:10.4161/cc.7.5.5486 · Cited by 44
Exploiting the mammalian target of rapamycin pathway in hematologic malignancies
Altman, J. K., & Platanias, L. C. (2008) · Current Opinion in Hematology · doi:10.1097/moh.0b013e3282f3deaa · Cited by 41
Harada, M., Benito, J., Yamamoto, S., Kaur, S., Arslan, D., Ramírez, S., Jacamo, R. O., Platanias, L. C., Matsushita, H., Fujimura, T., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6122 · Cited by 41
“AMPK is a known negative regulator of mTORC1 [41], and the pan-Pim kinase inhibitor or PIM1 siRNA has been shown to block mTORC1 activity by stimulating the phosphorylation and thus activation of AMPK [42].”
BackgroundJin, C., Liu, Z., Li, Y., Bu, H., Wang, Y., Xu, Y., Qiu, C., Shi, Y., Yuan, C., Li, R., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31800 · Cited by 37
“The phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR pathway is an essential intracellular signaling cascade.(16,17) Aberrant”
BackgroundSun, W., Depping, R., & JELKMANN, W. E. B. (2014) · Cell Death and Disease · doi:10.1038/cddis.2013.562 · Cited by 43
An overview of the mTOR pathway as a target in cancer therapy
Gentzler, R. D., Altman, J. K., & Platanias, L. C. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.677439 · Cited by 39
“4E-BP1 binds constitutively to eIF4E, when not in its phosphorylated form, and thus prevents eIF4E from associating with other proteins and forming the initiation factor complex required for capdependent mRNA translation [5,20].”
BackgroundInfluentialCheng, Y., Pan, Y., Pan, Y., & Wang, O. (2019) · Cancer Management and Research · doi:10.2147/cmar.s188007 · Cited by 42
Lin, Z., Wang, Z., Zhou, X., Zhang, M., Gao, D., Zhang, L., Wang, P., Chen, Y., Lin, Y., Zhao, B., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02746-w · Cited by 41
mTOR pathway and DNA damage response: A therapeutic strategy in cancer therapy
Pazhooh, R. D., Farnood, P. R., Asemi, Z., Mirsafaei, L., Yousefi, B., & Mirzaei, H. (2021) · DNA repair · doi:10.1016/j.dnarep.2021.103142 · Cited by 43
Schmidt, T., Dąbrowska, A., Waldron, J. A., Hodge, K., Koulouras, G., Gabrielsen, M., Munro, J., Tack, D. C., Harris, G., McGhee, E. J., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad030 · Cited by 41
“…of translation initiation factors including eIF4F is (i) tightly controlled in cellular programmes like proliferation and differentiation (76–78), (ii) can vary between tissues and iii) is often dramatically affected in many different cancers (59,79–81), regulation and dysregulation of…”
Episensitization: Defying Time’s Arrow
Oronsky, B. T., Oronsky, A. L., Lybeck, M., Oronsky, N. C., Scicinski, J. J., Carter, C. A., Day, R. M., Rodríguez‐Orengo, J. F., Rodriguez‐Torres, M., Fanger, G. R., et al. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00134 · Cited by 37
“This adaptive flexible responsiveness is known as phenotypic plasticity (16) and greatly increases the competitiveness of the cancer cell relative to non-neoplastic cells, allowing the tumor to adjust its phenotype to the local microenvironment, provided that the costs of an adaptive plastic response are not selective…”
BackgroundJung, H. J., Kim, J. H., Shim, J. S., & Kwon, H. J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.135632 · Cited by 38
Willett, M., Cowan, J. L., Vlasak, M., Coldwell, M. J., & Morley, S. (2009) · Cellular Signalling · doi:10.1016/j.cellsig.2009.05.009 · Cited by 40
Peppenelli, M. A., Arend, K. C., Cojohari, O., Moorman, N. J., & Chan, G. C. T. (2016) · Journal of Virology · doi:10.1128/jvi.02879-15 · Cited by 37
Analysis of PI3K/AKT/mTOR signalling pathway in high risk neuroblastic tumours.
Iżycka‐Świeszewska, E., Drożyńska, E., Rzepko, R., Kobierska‐Gulida, G., Grajkowska, W., Perek, D., & Balcerska, A. (2010) · PubMed · Cited by 36
β-Carotene Increases Muscle Mass and Hypertrophy in the Soleus Muscle in Mice
Kitakaze, T., Harada, N., Imagita, H., & Yamaji, R. (2015) · Journal of Nutritional Science and Vitaminology · doi:10.3177/jnsv.61.481 · Cited by 37
Lautaoja-Kivipelto, J. H., Lalowski, M. M., Nissinen, T. A., Hentilä, J., Shi, Y., Ritvos, O., Cheng, S., & Hulmi, J. J. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00526.2018 · Cited by 37
“During cachexia, decreased energy and growth signaling as well as increased content of cytokines such as myostatin/activins downregulate the activity of the mechanistic target of rapamycin (mTOR) (30, 38, 43), which is one of the most important regulators of protein, nucleotide, and lipid synthesis.”
BackgroundThoreen, C. C. (2013) · Biochemical Society Transactions · doi:10.1042/bst20130082 · Cited by 42
Chung, C., Chang, C.-H., Chen, S.-S., Wang, H.-H., Yen, J.-Y., Hsiao, C., Wu, N., Chen, Y., Huang, T., Wang, P., et al. (2013) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2013/943187 · Cited by 37
Wangpaichitr, M., Savaraj, N., Maher, J. C., Kurtoğlu, M., & Lampidis, T. J. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2334 · Cited by 35
Expression of PTEN and mTOR in pancreatic neuroendocrine tumors
Han, X., Ji, Y., Zhao, J., Xu, X., & Lou, W. (2013) · Tumor Biology · doi:10.1007/s13277-013-0849-1 · Cited by 34
Historical retrospective of the SRC oncogene and new perspectives (Review)
Simatou, A., Simatos, G., Goulielmaki, M., Spandidos, D. A., Baliou, S., & Zoumpourlis, V. (2020) · Molecular and Clinical Oncology · doi:10.3892/mco.2020.2091 · Cited by 44
“Recently, the mechanisms underlying SRC‑mediated acti‑ vation of mTOR signaling, a major downstream effector of the PI3K pathway, were found to be regulated by miRNA expres‑ sion in various cancer types (54,55).”
Patient-level proteomic network prediction by explainable artificial intelligence
Keyl, P., Bockmayr, M. L., Heim, D., Dernbach, G., Montavon, G., Müller, K., & Klauschen, F. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00278-4 · Cited by 45
Tzeng, T., Kong, L.-R., Chen, C., Shaw, C.-C., & Yang, C. (2009) · Plant and Cell Physiology · doi:10.1093/pcp/pcp114 · Cited by 34
“It has been shown that TOR interacts with the Regulatory-Associated Protein of TOR (RAPTOR) to activate p70 s6k ( Hara et al. 2002 , Kim et al. 2002 , Nojima et al. 2003 , Mamane et al. 2006 , Jacinto and Lorberg 2008 ).”
BackgroundRegulation of catalytic activity of S6 kinase 2 during cell cycle
Boyer, D., Quintanilla, R. H., & Lee-Fruman, K. K. (2007) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-007-9584-5 · Cited by 34
“Both S6K1 and S6K2 are regulated by the same phosphoinositide-3-kinase (PI3K)/Akt/mTOR pathways [8].”
BackgroundMalone, T., Schäfer, L., Simon, N., Heavey, S., Cuffe, S., Finn, S., Moore, G., & Gately, K. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107454 · Cited by 33
“HSF1 has been shown to drive translation by regulating ribosome biogenesis (Mamane et al., 2006; Santagata et al., 2013).”
BackgroundMetformin: a new option in cancer treatment
Belda-Iniesta, C., Pernía, O., & Simó, R. (2011) · Clinical & Translational Oncology · doi:10.1007/s12094-011-0669-y · Cited by 37
“This phosphorylation stimulates the GTPase activity function of TSC2 towards the G-protein Rheb and increases the levels of GDP-Rheb, downregulating its activity, and this results in inhibition of mTOR activity [9] (Fig.”
BackgroundInfluentialThe mTOR Pathway Regulates PKM2 to Affect Glycolysis in Esophageal Squamous Cell Carcinoma
He, X., Yiru, Y., Shui-sheng, S., Keyan, C., Yan, Z., Shanglin, C., Yuan, W., Dongming, C., Wangliang, Z., Bai, X., et al. (2018) · Technology in Cancer Research & Treatment · doi:10.1177/1533033818780063 · Cited by 35
“mTOR is phosphorylated by Akt1 at Ser2448, leading to downstream signaling by p-mTOR.(11) The premise of our study was to examine the regulatory relationship between the mTOR pathway and PKM2.”
Background
Metadata
- Authors
- Mamane, Y., Petroulakis, E., LeBacquer, O., & Sonenberg, N.
- Affiliations
- McGill University (CA)
- Corresponding author
- Sonenberg, N
- ORCID
- Sonenberg, N
- Venue
- Oncogene
- Published
- 2006-10-16
- Volume
- 25
- Issue
- 48
- Pages
- 6416-6422
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2165848665
- Cited by
- 607
- References
- 79
- Citations by year
- 2026: 2 · 2025: 10 · 2024: 4 · 2023: 28 · 2022: 14 · 2021: 7 · 2020: 23 · 2019: 16 · 2018: 32 · 2017: 26 · 2016: 28 · 2015: 41 · 2014: 41 · 2013: 40 · 2012: 41
- FWCI
- 4.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- mTOR, mRNA translation, translation initiation, PI3K/AKT/mTOR pathway, 4E-BP, S6K, cap-dependent translation, cancer therapy, nutrient signaling, cell growth
- MeSH terms
- Animals, Gene Expression Regulation, Humans, Mammals, Models, Genetic, Neoplasms, Peptide Chain Initiation, Translational, Protein Kinases, Signal Transduction, Phosphatidylinositol 3-Kinases, Ribosomal Protein S6 Kinases, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.